Johnson & Johnson (JNJ) and AbbVie (ABBV) are two major U.S. pharmaceutical companies with robust pipelines and global operations. Both companies have a strong presence in immunology, oncology and neuroscience areas. Other than that, J&J also has drugs for cardiovascular and metabolic diseases, pulmonary hypertension and infectious diseases, along with a strong presence in the medical devices segment.On the other hand, AbbVie entered the aesthetics market by acquiring Botox maker Allergan in 2020.It seems t ...

TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis  Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn's disease  SAN DIEGO, May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ul ...

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older  IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal studies          gMG patients taking IMAAVY demonstrated 20 months of lasting disease control and symptom relief in the pivotal Vivacity-MG3 study and ongoing open-label extension (OLE)SPRING HOUSE, Pa., April 30, 2025 /PRN ...

Core Insights - Major companies are increasing dividends to provide stability and reliable returns to investors amid market volatility [1] Johnson & Johnson - Announced a 4.8% increase in its quarterly dividend, resulting in an annual dividend of $5.20 and a dividend yield of 3.35% [2][4] - Has a strong track record with 64 years of consecutive dividend increases and a 3-year annualized dividend growth rate of 5.43% [2][4] - Faces challenges from tariffs estimated to cost $400 million this year, primarily affecting its medical technology business [4] - Engaged in share buybacks, spending nearly $3.1 billion over the last 12 months, representing about 0.8% of its market capitalization [5] Costco Wholesale - Increased its quarterly dividend from $1.16 to $1.30 per share, marking a notable 12% increase [7] - The indicated annual dividend is $5.20, but the dividend yield is low at 0.53%, significantly below the average yield of 3.3% for the largest consumer staples stocks [8] - Focuses on share buybacks as its primary method of returning capital, having spent nearly $3.8 billion on buybacks in the last 12 months, resulting in a buyback yield of nearly 6.5% [8][9] NASDAQ - Announced a 13% increase in its quarterly dividend, bringing the new dividend to $0.27, with an indicated yield of approximately 1.42% [10][11][12] - The company has spent $260 million on share buybacks since the beginning of 2024, which is about 0.6% of its market capitalization, with additional buyback capacity of $1.6 billion [13] - Achieved a debt paydown yield of nearly 2% over the last 12 months, indicating effective debt management [13]

Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S. manufacturing. Trump scored a major victory when Taiwan Semiconductor Manufacturing NYSE: TSM promised to invest $100 billion in U.S. facilities. Chip behemoth NVIDIA NASDAQ: NVDA recently made a similar announcement. It plans to produce “half a trillion dollars of AI infrastructure in the United States” over the ne ...

Core Insights - Johnson & Johnson announced promising results from the Phase 2b SunRISe-1 study of TAR-200, showing over 82% of patients achieved complete response (CR) and more than half remained cancer-free for at least one year [1][4] - TAR-200 is positioned as a transformative treatment for patients with BCG-unresponsive, high-risk non-muscle invasive bladder cancer (HR-NMIBC), particularly those ineligible for radical cystectomy [1][8] Company Overview - Johnson & Johnson is focused on healthcare innovation, aiming to provide less invasive and more effective treatment options for complex diseases [9] - The company has initiated a new drug application with the FDA for TAR-200 under the Real-Time Oncology Review program, following its Breakthrough Therapy Designation [6][4] Study Details - The SunRISe-1 study enrolled 85 patients, with a complete response rate of 82.4% and a median duration of response of 25.8 months [1][7] - The study specifically targets patients with carcinoma in situ, with or without papillary disease, who have not responded to BCG therapy [7] Treatment Efficacy - The treatment demonstrated a high level of sustained disease control, with 52.9% of responders maintaining CR at one year and 86.6% remaining cystectomy-free [1][2] - Most treatment-related adverse events were mild, with only 3.5% of patients discontinuing treatment due to adverse effects [2] Market Context - Bladder cancer is among the ten most common cancers globally, with limited treatment options available for patients who do not respond to initial BCG therapy [1][8] - High-risk non-muscle invasive bladder cancer accounts for 15-44% of NMIBC cases, characterized by high-grade tumors and a tendency to recur [8]

Core Insights - The Phase 2b SunRISe-1 study results indicate that over 82% of patients with high-risk non-muscle invasive bladder cancer achieved a complete response (CR), with more than half remaining cancer-free for at least one year after treatment [1][2][3] - TAR-200, an intravesical gemcitabine releasing system, shows promise in transforming treatment outcomes for patients who are BCG-unresponsive and ineligible for radical cystectomy [1][2][3] Study Results - As of March 2025, 82.4% of the 85 enrolled patients achieved CR, with a 95% confidence interval of 72.6-89.8 [1] - 52.9% of responders maintained CR at one year, and the median duration of response was 25.8 months [1] - At 12 months, 86.6% of responders remained cystectomy-free [1] Treatment Tolerability - The treatment was well-tolerated, with 83.5% of patients experiencing mild treatment-related adverse events, primarily low-grade urinary symptoms [1] - Only 3.5% of patients discontinued treatment due to adverse events, and there were no treatment-related deaths [1] Clinical Significance - The results were presented at the 2025 American Urological Association Annual Meeting, highlighting the potential of TAR-200 to address significant unmet needs in bladder cancer treatment [1][2] - The study emphasizes the importance of patient quality of life, as TAR-200 is designed to fit into patients' lives without interrupting their daily activities [1][2] Background on Bladder Cancer - Bladder cancer is among the ten most common cancers globally, with limited treatment options available for patients who do not respond to initial BCG therapy [1][4] - High-risk non-muscle invasive bladder cancer (HR-NMIBC) accounts for 15-44% of NMIBC cases and is characterized by a high likelihood of recurrence and progression [4] About TAR-200 - TAR-200 is an investigational system designed for sustained local release of gemcitabine into the bladder, currently being evaluated in multiple clinical trials [2][3] - The ongoing Phase 2b SunRISe-1 study specifically targets patients with BCG-unresponsive HR-NMIBC [3]

Group 1: Johnson & Johnson - Johnson & Johnson plans to increase its U.S. manufacturing investments to over $55 billion over the next four years, which is 25% more than the previous four years [2] - The company is facing challenges such as thousands of talc-related lawsuits and potential revenue loss due to the Inflation Reduction Act, which allows Medicare to negotiate drug prices [3] - Despite these challenges, Johnson & Johnson has a strong business model, significant adaptability, and has generated consistent revenue, making it a reliable investment option [4][5] - The company has maintained a AAA credit rating from Standard & Poor's and has increased its dividends for 63 consecutive years, establishing itself as a Dividend King [5][6] Group 2: Novartis - Novartis is investing $23 billion over five years to enhance its U.S. manufacturing capabilities, aiming to locally produce 100% of the medicines sold in the U.S. [7] - The company anticipates a compound annual growth rate (CAGR) of 5% in revenue through 2029, despite losing U.S. patent exclusivity for its heart failure medicine Entresto, which generated $7.8 billion in sales last year [8] - New products, such as Fabhalta, are expected to help fill the revenue gap from off-patent drugs, supporting Novartis's growth trajectory [9] - Novartis has increased its dividends for 28 consecutive years, making it appealing to income-focused investors [10]

The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates of endoscopic normalisationb at Week 44 compared with placebo.2,6,7,8,9 Guselkumab is now approved for the treatment of ulcerative colitis in addition to existing indications of plaque psoriasis and psoriatic arthritis in the European Union.2 Beerse, Belgium (25 April 2025) – Johnson & Johnson today announced that the Europea ...

If you want to collect a lot of dividend income, it's important to focus on more than just a stock's current yield. Stocks that consistently grow their payouts over the years can be far more valuable investments to hang on to because that can ensure your dividend income is rising, possibly at a higher rate than inflation. Three stocks which have impressive track records for dividend growth are Walmart (WMT 0.20%), Johnson & Johnson (JNJ -1.49%), and Procter & Gamble (PG -1.27%). They are not just your regul ...